Posters and publications

MK2 pathway inhibitor

Selective Inhibition of the p38α MAPK–MK2 Axis Inhibits Inflammatory Cues Including Inflammasome Priming Signals »

Wang C, Hockerman S, Jacobsen EJ, et al. J Exp Med. 2018;215(5):1315-1325.
doi: 10.1084/jem.20172063.
Selective p38α MAPK Inhibitor Shows Promise »

McHugh, J. Nature Reviews Rheumatol. 2018;14(6): 321. 
Inhibition of the Stromal p38MAPK/MK2 Pathway Limits Breast Cancer Metastases and Chemotherapy-Induced Bone Loss »

Murali B, Ren Q, Luo X, et al. Cancer Res. 2018;78(19):5618-5630. doi: 10.1158/0008-5472.CAN-18-0234
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MK2 Inhibitor ATI-450 in Healthy Subjects: A Placebo-Controlled, Randomized Phase 1 Study »

Gordon D, Monahan J, et al. Clinical Pharmacology: Advances and Applications 2021:13 123–134